The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn

Area of Science:

• Pharmacology
• Endocrinology
• Biologics

Background:

• Insulin products reclassified as biologics under the BPCI Act enable biosimilar development.
• Interchangeable biosimilar status requires further switch trials beyond non-inferiority.
• Insulin glargine-yfgn achieved interchangeable status, marking a significant advancement.

Purpose of the Study:

• To evaluate the efficacy and safety of insulin glargine-yfgn compared to reference insulin glargine.
• To assess the impact of switching between insulin glargine-yfgn and reference insulin glargine.
• To highlight the potential of interchangeable biosimilars to improve patient access and reduce costs.

Main Methods:

• INSTRIDE 1 & 2 trials: Non-inferiority of insulin glargine-yfgn vs. reference insulin glargine for glucose reduction and safety.
• INSTRIDE 3 trial: Assessed safety and efficacy during treatment switches between the two insulins.
• Analysis of cost-effectiveness and market impact of biosimilar insulin.

Main Results:

• Insulin glargine-yfgn demonstrated non-inferiority in blood glucose reduction and adverse event profiles.
• Switching between insulin glargine-yfgn and reference insulin glargine did not result in statistically significant changes.
• Insulin glargine-yfgn is significantly lower priced, increasing competition and potentially lowering overall insulin costs.

Conclusions:

• Insulin glargine-yfgn is a safe and effective interchangeable biosimilar to reference insulin glargine.
• It can be substituted at the pharmacy level, improving patient access to affordable insulin therapy.
• Increased awareness and education on biosimilars are crucial for provider adoption and patient benefit.